<unk>  is both a risk factor and precursor of invasive carcinoma. Furthermore, it is a non-obligate precursor. In other words,<unk>  represents a distinct entity in the developmental pathway of cancer that does not guarantee invasive carcinoma. That being said, the historical approach of radical mastectomy (surgical removal of entire breast and axillary lymph nodes) has been substituted by more conservative approaches. Observation is the preferred management option if<unk>  is found to occur alone without accompanying infiltrating or invasive carcinoma.<unk>  may be treated with close clinical follow-up (frequent scheduled checkups) and mammographic screening, tamoxifen or related hormone controlling drugs to reduce the risk of developing cancer, or, if patients and providers would like a less conservative option, bilateral prophylactic mastectomy. Some surgeons consider bilateral prophylactic mastectomy to be overly aggressive treatment except for certain high-risk cases. This is in part due to the fact that multiple studies have shown no significant different in mortality due to breast cancer between women who underwent surveillance and those who elected for the mastectomy. When Lobular Neoplasia, or specifically,<unk> , is found on core needle biopsy during routine workups, the National Comprehensive Cancer Network (NCCN) recommends the surgeon perform an excisional biopsy of the region to allow pathologists to rule out concurrent DCIS or invasive cancer. It has been widely reported in the literature that 10-30% of patients with a diagnosis of<unk>  on core needle biopsy will receive an upstaged diagnosis after excisional. If<unk>  remains the only diagnosis after the excisional biopsy, NCCN guidelines recommend clinical follow-up every 6–12 months with annual diagnostic mammograms.
Lobular carcinoma in situ
Ductal carcinoma in situ
Sister Mary Joseph nodule
Invasive lobular carcinoma
Invasive carcinoma of no special type
Lymphoepithelioma-like carcinoma
Focal nodular hyperplasia
Atypical ductal hyperplasia